The Experts below are selected from a list of 1452 Experts worldwide ranked by ideXlab platform
Sharifah Syed Hassan - One of the best experts on this subject based on the ideXlab platform.
-
Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication
Virology journal, 2017Co-Authors: Siti Aisyah Abdul Ahmad, Uma Devi Palanisamy, Bimo Ario Tejo, Miaw Fang Chew, Hong-wai Tham, Sharifah Syed HassanAbstract:The rapid rise and spread in dengue cases, together with the unavailability of safe vaccines and effective antiviral drugs, warrant the need to discover and develop novel anti-dengue treatments. In this study the antiviral activity of geraniin, extracted from the rind of Nephelium lappaceum, against dengue virus type-2 (DENV-2) was investigated. Geraniin was prepared from Nephelium lappaceum rind by reverse phase C-18 column chromatography. Cytotoxicity of geraniin towards Vero cells was evaluated using MTT assay while IC50 value was determined by plaque reduction assay. The mode-of-action of geraniin was characterized using the virucidal, attachment, penetration and the time-of-addition assays’. Docking experiments with geraniin molecule and the DENV envelope (E) protein was also performed. Finally, recombinant E Domain III (rE-DIII) protein was produced to physiologically test the binding of geraniin to DENV-2 E-DIII protein, through ELISA competitive binding assay. Cytotoxicity assay confirmed that geraniin was not toxic to Vero cells, even at the highest concentration tested. The compound exhibited DENV-2 plaque formation inhibition, with an IC50 of 1.75 μM. We further revealed that geraniin reduced viral infectivity and inhibited DENV-2 from attaching to the cells but had little effect on its penetration. Geraniin was observed to be most effective when added at the early stage of DENV-2 infection. Docking experiments showed that geraniin binds to DENV E protein, specifically at the DIII region, while the ELISA competitive binding assay confirmed geraniin’s interaction with rE-DIII with high affinity. Geraniin from the rind of Nephelium lappaceum has antiviral activity against DENV-2. It is postulated that the compound inhibits viral attachment by binding to the E-DIII protein and interferes with the initial cell-virus interaction. Our results demonstrate that geraniin has the potential to be developed into an effective antiviral treatment, particularly for early phase dengue viral infection.
-
Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication
BMC, 2017Co-Authors: Siti Aisyah Abdul Ahmad, Bimo Ario Tejo, Miaw Fang Chew, Hong-wai Tham, Uma D. Palanisamy, Sharifah Syed HassanAbstract:Abstract Background The rapid rise and spread in dengue cases, together with the unavailability of safe vaccines and effective antiviral drugs, warrant the need to discover and develop novel anti-dengue treatments. In this study the antiviral activity of geraniin, extracted from the rind of Nephelium lappaceum, against dengue virus type-2 (DENV-2) was investigated. Methods Geraniin was prepared from Nephelium lappaceum rind by reverse phase C-18 column chromatography. Cytotoxicity of geraniin towards Vero cells was evaluated using MTT assay while IC50 value was determined by plaque reduction assay. The mode-of-action of geraniin was characterized using the virucidal, attachment, penetration and the time-of-addition assays’. Docking experiments with geraniin molecule and the DENV envelope (E) protein was also performed. Finally, recombinant E Domain III (rE-DIII) protein was produced to physiologically test the binding of geraniin to DENV-2 E-DIII protein, through ELISA competitive binding assay. Results Cytotoxicity assay confirmed that geraniin was not toxic to Vero cells, even at the highest concentration tested. The compound exhibited DENV-2 plaque formation inhibition, with an IC50 of 1.75 μM. We further revealed that geraniin reduced viral infectivity and inhibited DENV-2 from attaching to the cells but had little effect on its penetration. Geraniin was observed to be most effective when added at the early stage of DENV-2 infection. Docking experiments showed that geraniin binds to DENV E protein, specifically at the DIII region, while the ELISA competitive binding assay confirmed geraniin’s interaction with rE-DIII with high affinity. Conclusions Geraniin from the rind of Nephelium lappaceum has antiviral activity against DENV-2. It is postulated that the compound inhibits viral attachment by binding to the E-DIII protein and interferes with the initial cell-virus interaction. Our results demonstrate that geraniin has the potential to be developed into an effective antiviral treatment, particularly for early phase dengue viral infection
Cesário F. Virgens - One of the best experts on this subject based on the ideXlab platform.
-
Thermal decomposition of Nephelium lappaceum L. peel
Journal of Thermal Analysis and Calorimetry, 2019Co-Authors: João Daniel S. Castro, Cesário F. VirgensAbstract:Influence of chemical pretreatment in thermal behavior of Nephelium lappaceum L. peels was studied through thermogravimetric analysis, SEM, X-ray diffraction, FTIR and EDXRF. Results of derivate thermogravimetry were deconvoluted with Fraser–Suzuki function, demonstrating that the distribution of pseudo-components is affected by chemical pretreatment, where sulfuric acid pretreated sample (Ras) has not indicated the cellulose pseudo-component peak and the phosphoric acid pretreated sample (Rap) also did not demonstrate the lignin peak, indicating itself to be an effective tool in the prediction of pseudo-components of lignocellulosic samples. This result corroborates with FTIR spectra and XRD. The sample Rna (sodium hydroxide treated) has indicated modifications in cellulose crystalline structure, conversion of cellulose I/II, revealed by XRD. An EDXRF analysis demonstrated that the chemical pretreatment also influenced the distribution of minerals, constituted essentially of Na, Mg, Fe, K, Al and Cl. This change is evidenced when carrying out statistical analysis of the samples, and principal component analysis applied in EDXRF data revealed statistical differences between samples, separating in distinct quadrants.
Siti Aisyah Abdul Ahmad - One of the best experts on this subject based on the ideXlab platform.
-
Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication
Virology journal, 2017Co-Authors: Siti Aisyah Abdul Ahmad, Uma Devi Palanisamy, Bimo Ario Tejo, Miaw Fang Chew, Hong-wai Tham, Sharifah Syed HassanAbstract:The rapid rise and spread in dengue cases, together with the unavailability of safe vaccines and effective antiviral drugs, warrant the need to discover and develop novel anti-dengue treatments. In this study the antiviral activity of geraniin, extracted from the rind of Nephelium lappaceum, against dengue virus type-2 (DENV-2) was investigated. Geraniin was prepared from Nephelium lappaceum rind by reverse phase C-18 column chromatography. Cytotoxicity of geraniin towards Vero cells was evaluated using MTT assay while IC50 value was determined by plaque reduction assay. The mode-of-action of geraniin was characterized using the virucidal, attachment, penetration and the time-of-addition assays’. Docking experiments with geraniin molecule and the DENV envelope (E) protein was also performed. Finally, recombinant E Domain III (rE-DIII) protein was produced to physiologically test the binding of geraniin to DENV-2 E-DIII protein, through ELISA competitive binding assay. Cytotoxicity assay confirmed that geraniin was not toxic to Vero cells, even at the highest concentration tested. The compound exhibited DENV-2 plaque formation inhibition, with an IC50 of 1.75 μM. We further revealed that geraniin reduced viral infectivity and inhibited DENV-2 from attaching to the cells but had little effect on its penetration. Geraniin was observed to be most effective when added at the early stage of DENV-2 infection. Docking experiments showed that geraniin binds to DENV E protein, specifically at the DIII region, while the ELISA competitive binding assay confirmed geraniin’s interaction with rE-DIII with high affinity. Geraniin from the rind of Nephelium lappaceum has antiviral activity against DENV-2. It is postulated that the compound inhibits viral attachment by binding to the E-DIII protein and interferes with the initial cell-virus interaction. Our results demonstrate that geraniin has the potential to be developed into an effective antiviral treatment, particularly for early phase dengue viral infection.
-
Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication
BMC, 2017Co-Authors: Siti Aisyah Abdul Ahmad, Bimo Ario Tejo, Miaw Fang Chew, Hong-wai Tham, Uma D. Palanisamy, Sharifah Syed HassanAbstract:Abstract Background The rapid rise and spread in dengue cases, together with the unavailability of safe vaccines and effective antiviral drugs, warrant the need to discover and develop novel anti-dengue treatments. In this study the antiviral activity of geraniin, extracted from the rind of Nephelium lappaceum, against dengue virus type-2 (DENV-2) was investigated. Methods Geraniin was prepared from Nephelium lappaceum rind by reverse phase C-18 column chromatography. Cytotoxicity of geraniin towards Vero cells was evaluated using MTT assay while IC50 value was determined by plaque reduction assay. The mode-of-action of geraniin was characterized using the virucidal, attachment, penetration and the time-of-addition assays’. Docking experiments with geraniin molecule and the DENV envelope (E) protein was also performed. Finally, recombinant E Domain III (rE-DIII) protein was produced to physiologically test the binding of geraniin to DENV-2 E-DIII protein, through ELISA competitive binding assay. Results Cytotoxicity assay confirmed that geraniin was not toxic to Vero cells, even at the highest concentration tested. The compound exhibited DENV-2 plaque formation inhibition, with an IC50 of 1.75 μM. We further revealed that geraniin reduced viral infectivity and inhibited DENV-2 from attaching to the cells but had little effect on its penetration. Geraniin was observed to be most effective when added at the early stage of DENV-2 infection. Docking experiments showed that geraniin binds to DENV E protein, specifically at the DIII region, while the ELISA competitive binding assay confirmed geraniin’s interaction with rE-DIII with high affinity. Conclusions Geraniin from the rind of Nephelium lappaceum has antiviral activity against DENV-2. It is postulated that the compound inhibits viral attachment by binding to the E-DIII protein and interferes with the initial cell-virus interaction. Our results demonstrate that geraniin has the potential to be developed into an effective antiviral treatment, particularly for early phase dengue viral infection
Jean-maurille Ouamba - One of the best experts on this subject based on the ideXlab platform.
-
Thermal Properties of Monoglycerides from Nephelium lappaceum L. Oil, as a Natural Source of Saturated and Monounsaturated Fatty Acids
Industrial & Engineering Chemistry Research, 2013Co-Authors: Valentin Romain, Adolphe Christian Ngakegni-limbili, Zéphirin Mouloungui, Jean-maurille OuambaAbstract:The present paper studied the transformations of reserve lipids (RLs) of the species Nephelium lappaceum Linn (N. lappaceum). The triacylglycerols (TAGs) in this species are composed of C18:1, C20:...
Uma Devi Palanisamy - One of the best experts on this subject based on the ideXlab platform.
-
The insulin-sensitising properties of the ellagitannin geraniin and its metabolites from Nephelium lappaceum rind in 3T3-L1 cells.
International journal of food sciences and nutrition, 2020Co-Authors: Asiri Perera, So Ha Ton, Mohanambal Moorthy, Uma Devi PalanisamyAbstract:In this study, the insulin-like and insulin sensitising effects of the ellagitannins geraniin, corilagin, ellagic acid, gallic acid and Nephelium lappaceum rind extract in 3T3-L1 adipocytes was inv...
-
Acute oral toxicity of the ellagitannin geraniin and a geraniin-enriched extract from Nephelium lappaceum L rind in Sprague Dawley rats
Heliyon, 2019Co-Authors: Mohanambal Moorthy, Joon Joon Khoo, Uma Devi PalanisamyAbstract:Despite the lack of its toxicity evaluation, traditional herbal products are being widely used for various health indications. Geraniin, an ellagitannin, is a bioactive compound found in many traditional herbal medicines. In spite its numerous health benefits ranging from anti-inflammatory, anti-hyperglycaemic, hepatoprotective, anti-cancer and anti-microbial, no toxicity data on geraniin is available. The objective of this study is to evaluate the acute oral toxicity of geraniin and an enriched geraniin-extract of Nephelium lappaceum L rind. This study followed the guidelines of the OECD 423 acute oral toxicity test. Subsequent to a single oral administration of the test compounds, the rats were observed for 14 days for signs of toxicity and mortality. Following euthanasia, full blood count, biochemistry of blood and histopathology assessment of organs were carried out. All parameters analysed indicated insignificant difference compared to control. The LD50 cut-off values for both geraniin and geraniin-enriched extract was established to be 2000 mg/kg b. w., following a single oral dose. It was however observed that the hepatocytes of three geraniin-administered rats exhibited a 'foamy appearance'. As such, the no-observed-adverse-effect level of geraniin is below 2000 mg/kg, while that of geraniin-enriched extract is up to 2000 mg/kg. Further detailed toxicity studies are required to establish geraniin or its enriched extract from Nephelium lappaceum L rind safe for human consumption.
-
Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication
Virology journal, 2017Co-Authors: Siti Aisyah Abdul Ahmad, Uma Devi Palanisamy, Bimo Ario Tejo, Miaw Fang Chew, Hong-wai Tham, Sharifah Syed HassanAbstract:The rapid rise and spread in dengue cases, together with the unavailability of safe vaccines and effective antiviral drugs, warrant the need to discover and develop novel anti-dengue treatments. In this study the antiviral activity of geraniin, extracted from the rind of Nephelium lappaceum, against dengue virus type-2 (DENV-2) was investigated. Geraniin was prepared from Nephelium lappaceum rind by reverse phase C-18 column chromatography. Cytotoxicity of geraniin towards Vero cells was evaluated using MTT assay while IC50 value was determined by plaque reduction assay. The mode-of-action of geraniin was characterized using the virucidal, attachment, penetration and the time-of-addition assays’. Docking experiments with geraniin molecule and the DENV envelope (E) protein was also performed. Finally, recombinant E Domain III (rE-DIII) protein was produced to physiologically test the binding of geraniin to DENV-2 E-DIII protein, through ELISA competitive binding assay. Cytotoxicity assay confirmed that geraniin was not toxic to Vero cells, even at the highest concentration tested. The compound exhibited DENV-2 plaque formation inhibition, with an IC50 of 1.75 μM. We further revealed that geraniin reduced viral infectivity and inhibited DENV-2 from attaching to the cells but had little effect on its penetration. Geraniin was observed to be most effective when added at the early stage of DENV-2 infection. Docking experiments showed that geraniin binds to DENV E protein, specifically at the DIII region, while the ELISA competitive binding assay confirmed geraniin’s interaction with rE-DIII with high affinity. Geraniin from the rind of Nephelium lappaceum has antiviral activity against DENV-2. It is postulated that the compound inhibits viral attachment by binding to the E-DIII protein and interferes with the initial cell-virus interaction. Our results demonstrate that geraniin has the potential to be developed into an effective antiviral treatment, particularly for early phase dengue viral infection.
-
Acute and sub chronic oral toxicity assessment of the ethanolic extract from the rind of Nephelium lappaceum in rats
Journal of Pharmacology and Toxicology, 2012Co-Authors: Shonia Subramaniam, Srikumar Chakravarthi, Uma Devi Palanisamy, Ammu Kutty Radhakrishnan, Nagaraja HaleagraharaAbstract:Nephelium lappaceum is a tropical fruit native to Malaysia. The rind of N. lappaceum, is having extremely high antioxidant and free radical scavenging activities. The ethanol extract from the rind of Nephelium lappaceum was evaluated for acute and sub-chronic toxicity study in Sprague Dawley rats. In the acute study, a single oral administration of N. lappaceum rind extract (50, 200, 1000 and 2000 mg kg⁻¹) was administered to rats for 14 days. In the sub chronic toxicity study, the extract was administered to rats (500, 2000 mg kg⁻¹) for 28 days. There was no mortality, or adverse effects observed in rats. There was no significant difference observed in relative organ weights and the biochemical analysis (serum urea, creatinine, ALP, AST and total protein). Histological observation of liver and kidney also did not reveal any significant changes. In conclusion, present study showed that the lethal dose of ethanol extract of Nephelium lappaceum rind is more than 2000 mg kg⁻¹ and there is a huge margin of safety for the therapeutic use. No-observed-adverse-effect-level (NOEL) of the extract is considered to be up to 2000 mg kg⁻¹ day⁻¹ for 28 days in rats.
-
rapid isolation of geraniin from Nephelium lappaceum rind waste and its anti hyperglycemic activity
Food Chemistry, 2011Co-Authors: Uma Devi Palanisamy, Lai Teng Ling, Thamilvaani Manaharan, David R AppletonAbstract:Abstract Recently we confirmed the ability of ethanolic Nephelium lappaceum L. rind extract to act as anti-hyperglycemic agent. Geraniin, an ellagitannin, was identified as the major bioactive compound isolated from the ethanolic Nephelium lappaceum L. rind extract. In this study, we describe the rapid isolation of geraniin from the above plant. In addition to its extremely high anti-oxidant activity and low pro-oxidant capability, geraniin is seen to possess in vitro hypoglycemic activity (alpha-glucosidase inhibition: IC 50 = 0.92 μg/ml and alpha-amylase inhibition: IC 50 = 0.93 μg/ml), aldol reductase inhibition activity (IC 50 = 7 μg/ml) and has the ability to prevent the formation of advanced glycation end-products (AGE). Geraniin was observed to exhibit these properties at more significant levels compared to the positive controls acarbose (carbohydrate hydrolysis inhibitor), quercetin (aldol reductase inhibitor) and green tea (AGE inhibitor). Geraniin therefore, has the potential to be developed into an anti-hyperglycemic agent. Our findings also strongly support the use of a geraniin-standardised N. lappaceum extract in the management of hyperglycemia.